<DOC>
	<DOCNO>NCT01744912</DOCNO>
	<brief_summary>The purpose study determine whether ublituximab combination lenalidomide ( Revlimid® ) safe effective patient B-Cell Lymphoid Malignancies relapse refractory CD20 direct antibody therapy</brief_summary>
	<brief_title>Ublituximab Combination With Lenalidomide Patients With B-Cell Lymphoid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Relapsed refractory Bcell nonHodgkins Lymphoma ( NHL ) , Chronic Lymphocytic Leukemia ( CLL ) Small Lymphocytic Lymphoma ( SLL ) Patients must receive least one prior line therapy antiCD20 antibody ( i.e . rituximab , ofatumumab , etc . ) antiCD20 antibody contain regimen Measurable evaluable Disease Eastern Cooperative Oncology Group performance status 0 , 1 2 Patients ineligible high dose combination chemotherapy + stem cell transplant No active chronic infection Hepatitis B C history HIV base negative serology All study participant must register mandatory RevAssist® program , willing able comply requirement RevAssist® Prior chemotherapy , investigational therapy radiotherapy within 3 week study entry Prior autologous allogeneic stem cell transplantation within 6 month study entry History severe hypersensitivity anaphylaxis prior murine mouse/human chimeric antibody , component ublituximab , prior lenalidomide thalidomide Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness would limit compliance study requirement History deep vein thrombosis ( DVT ) pulmonary embolus ( PE ) six month prior Day 1 Cycle 1 Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>immunomodulatory agent</keyword>
	<keyword>ublituximab</keyword>
	<keyword>lenalidomide</keyword>
</DOC>